Compare ZJYL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZJYL | QNCX |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 19.9M |
| IPO Year | 2020 | 2019 |
| Metric | ZJYL | QNCX |
|---|---|---|
| Price | $2.40 | $0.90 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 568.1K | ★ 690.4K |
| Earning Date | 08-20-2025 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.40 | ★ $0.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.08 |
| 52 Week High | $4.50 | $4.55 |
| Indicator | ZJYL | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 38.66 |
| Support Level | $1.94 | $0.79 |
| Resistance Level | $2.67 | $0.98 |
| Average True Range (ATR) | 0.38 | 0.07 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 12.16 | 5.95 |
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.